Patient Guide: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 50 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06890884
Status: 🟢 Enrolling Now
Condition: Lymphoma, Large B-Cell, Diffuse
Phase: PHASE2

Where You Can Participate

This study is available at 50 locations across the country.

Top locations include:
  • • Mobile, Alabama
  • • Glendale, Arizona
  • • Walnut Creek, California
  • • And 47 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) - Join Clinical Trial NCTNCT06890884

How to Join This Clinical Trial - NCTNCT06890884

Learn how to participate in this PHASE2 trial studying an investigational therapy for Lymphoma, Large B-Cell, Diffuse. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Lymphoma, Large B-Cell, Diffuse. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Lymphoma, Large B-Cell, Diffuse
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06890884 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 50 locations. Find a study site near you:

Clinical Research Site

Mobile, Alabama 36607 - United States

Status: RECRUITING

Clinical Research Site

Glendale, Arizona 85304 - United States

Status: RECRUITING

Clinical Research Site

Walnut Creek, California 94598 - United States

Status: RECRUITING

Clinical Research Site

Orange City, Florida 32763 - United States

Status: RECRUITING

Clinical Research Site

Chicago, Illinois 60637 - United States

Status: RECRUITING

Clinical Research Site

Iowa City, Iowa 52242 - United States

Status: RECRUITING

Clinical Research Site

Waukee, Iowa 50263 - United States

Status: RECRUITING

Clinical Research Site

Edgewood, Kentucky 41017 - United States

Status: RECRUITING

Clinical Research Site

Elizabethtown, Kentucky 42701 - United States

Status: RECRUITING

Clinical Research Site

Lexington, Kentucky 40503 - United States

Status: RECRUITING

And 40 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Lymphoma, Large B-Cell, Diffuse:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships